The DOI matches its Crossref record; 587 of the 587 references it cites were found in a registry or an index.
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Open accessAbstract
Anthracyclines have been important and effective treatments against a number of cancers since their discovery. However, their use in therapy has been complicated by severe side effects and toxicity that occur during or after treatment, including cardiotoxicity. The mode of action of anthracyclines is complex, with several mechanisms proposed. It is possible that their high toxicity is due to the large set of processes involved in anthracycline action. The development of resistance is a major barrier to successful treatment when using anthracyclines. This resistance is based on a series of mechanisms that have been studied and addressed in recent years. This work provides an overview of the anthracyclines used in cancer therapy. It discusses their mechanisms of activity, toxicity, and chemoresistance, as well as the approaches used to improve their activity, decrease their toxicity, and overcome resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
6 retracted
Lee, K., Qian, D. Z., Rey, S., Wei, H., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812801106 · Cited by 289
RetractedZhu, K., Xiao‐Long, M., & Zhang, C. (2017) · Oncotarget · doi:10.18632/oncotarget.17985 · Cited by 97
RetractedDas, S., Mukherjee, P., Chatterjee, R., Jamal, Z., & Chatterji, U. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0409 · Cited by 85
RetractedJoshi, N., Hajizadeh, F., Dezfouli, E. A., Zekiy, A. O., Nabi‐Afjadi, M., Mousavi, S. M., Hojjat‐Farsangi, M., Karpisheh, V., Mahmoodpoor, A., Hassannia, H., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119369 · Cited by 52
RetractedXiao, Y., Deng, T., Su, C., & Shang, Z. (2017) · Oncology Letters · doi:10.3892/ol.2017.6076 · Cited by 49
RetractedZhang, K., Chen, D., Wang, X., Zhang, S., Wang, J., Gao, Y., & Yan, B. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12010385 · Cited by 29
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Topological domains in mammalian genomes identified by analysis of chromatin interactions
Dixon, J. R., Selvaraj, S., Yue, F., Kim, A., Li, Y., Shen, Y., Hu, M., Liu, J. S., & Ren, B. (2012) · Nature · doi:10.1038/nature11082 · Cited by 6,829
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Principles of bioactive lipid signalling: lessons from sphingolipids
Hannun, Y. A., & Obeid, L. M. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2329 · Cited by 3,333
Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase
Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., Tran, H., Ross, S. E., Mostoslavsky, R., Cohen, H. Y., et al. (2004) · Science · doi:10.1126/science.1094637 · Cited by 3,239
Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2)
Bentley, S. D., Chater, K. F., Cerdeño-Tárraga, A.-M., Challis, G. L., Thomson, N. R., James, K. D., Harris, D. E., Quail, M. A., Kieser, H., Harper, D., et al. (2002) · Nature · doi:10.1038/417141a · Cited by 3,233
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
Tacar, O., Sriamornsak, P., & Dass, C. R. (2013) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01567.x · Cited by 2,465
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
DNA double-strand breaks: signaling, repair and the cancer connection
Khanna, K. K., & Jackson, S. P. (2001) · Nature Genetics · doi:10.1038/85798 · Cited by 2,455
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Chang, F., Lehmann, B., Terrian, D. M., Milella, M., Tafuri, A., et al. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.10.001 · Cited by 2,284
Dysregulated pH: a perfect storm for cancer progression
Webb, B. A., Chimenti, M., Jacobson, M. P., & Barber, D. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3110 · Cited by 2,237
Sensors and regulators of intracellular pH
Casey, J. R., Grinstein, S., & Orlowski, J. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2820 · Cited by 2,218
Ferroptosis as a target for protection against cardiomyopathy
Fang, X., Wang, H., Han, D., Xie, E., Yang, X., Wei, J., Gu, S., Gao, F., Zhu, N., Yin, X., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821022116 · Cited by 2,127
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L.-S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. H. (2012) · Nature Medicine · doi:10.1038/nm.2919 · Cited by 1,948
Holler, N., Zaru, R., Micheau, O., Thome, M., Attinger, A., Valitutti, S., Bodmer, J.-L., Schneider, P., Seed, B., & Tschopp, J. (2000) · Nature Immunology · doi:10.1038/82732 · Cited by 1,938
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
Pommier, Y., Leo, E., Zhang, H., & Marchand, C. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.04.012 · Cited by 1,829
Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
Li, X., Lewis, M. T., Huang, J., Gutierrez, C., Osborne, C. K., Wu, M.-F., Hilsenbeck, S. G., Pavlick, A., Zhang, X., Chamness, G. C., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn123 · Cited by 1,794
Targeting DNA topoisomerase II in cancer chemotherapy
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2607 · Cited by 1,791
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
Whole–genome characterization of chemoresistant ovarian cancer
Patch, A.-M., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,569
ESHRE Guideline: management of women with premature ovarian insufficiency
(2016) · Human Reproduction · doi:10.1093/humrep/dew027 · Cited by 1,555
Expression of a multidrug-resistance gene in human tumors and tissues.
Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.265 · Cited by 1,544
Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance
Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00193 · Cited by 1,451
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., & Moens, A. L. (2012) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.03.006 · Cited by 1,414
Expression of Multidrug Resistance Gene in Human Cancers
Goldstein, L. J., Galski, H., Fojo, A., Willingham, M., Lai, S.-L., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G. M., et al. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.2.116 · Cited by 1,290
Larue, L., & Bellacosa, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209091 · Cited by 1,228
Cancer Genetics and Epigenetics: Two Sides of the Same Coin?
You, J. S., & Jones, P. A. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.008 · Cited by 1,167
A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P. G., Manova-Todorova, K., Leversha, M., Hogg, N., Seshan, V. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.042 · Cited by 1,085
Post‐translational modifications and activation of p53 by genotoxic stresses
Appella, E., & Anderson, C. W. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02225.x · Cited by 1,079
Chatterjee, K., Zhang, J., Honbo, N., & Karliner, J. S. (2010) · Cardiology · doi:10.1159/000265166 · Cited by 1,065
Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044
Glutathione in Cancer Biology and Therapy
Estrela, J. M., Ortega, A., & Obrador, E. (2006) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360500523878 · Cited by 1,041
Jang, S. C., Kim, O. Y., Yoon, C. M., Choi, D.-S., Roh, T.-Y., Park, J., Nilsson, J., Lötvall, J., Kim, Y.-K., & Gho, Y. S. (2013) · ACS Nano · doi:10.1021/nn402232g · Cited by 1,022
ABC Multidrug Transporters: Structure, Function and Role in Chemoresistance
Sharom, F. J. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.1.105 · Cited by 973
P-Glycoprotein, a gatekeeper in the blood–brain barrier
Schinkel, A. H. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00085-4 · Cited by 960
Thomas, H., & Coley, H. M. (2003) · Cancer Control · doi:10.1177/107327480301000207 · Cited by 931
The anthracyclines: will we ever find a better doxorubicin?
Weiss, R. B. (1992) · PubMed · Cited by 918
The role of FLT3 in haematopoietic malignancies
Stirewalt, D. L., & Radich, J. P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1169 · Cited by 865
(2002) · PubMed · Cited by 840
Regulation of secondary metabolism in streptomycetes
Bibb, M. J. (2005) · Current Opinion in Microbiology · doi:10.1016/j.mib.2005.02.016 · Cited by 821
Ma, S., Lee, T. K., Zheng, B.-J., Chan, K. W., & Guan, X.-Y. (2008) · Oncogene · doi:10.1038/sj.onc.1210811 · Cited by 775
Flexibility in the ABC transporter MsbA: Alternating access with a twist
Ward, A., Reyes, C. L., Yu, J., Roth, C. B., & Chang, G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709388104 · Cited by 771
Nanoparticle Surface Functionalization: How to Improve Biocompatibility and Cellular Internalization
Sanità, G., Carrese, B., & Lamberti, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.587012 · Cited by 765
Anthracycline-Induced Cardiotoxicity
Shan, K., Lincoff, A. M., & Young, J. B. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00008 · Cited by 749
Sethi, T., Rintoul, R. C., Moore, S. M., MacKinnon, A. C., Salter, D., Choo, C., Chilvers, E. R., Dransfield, I., Donnelly, S. C., Strieter, R., et al. (1999) · Nature Medicine · doi:10.1038/9511 · Cited by 739
Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733
Regulation and function of the p53 tumor suppressor protein
Ryan, K. M., Phillips, A. C., & Vousden, K. H. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00216-7 · Cited by 721
Ma, Y., Adjemian, S., Mattarollo, S. R., Yamazaki, T., Aymeric, L., Yang, H., Portela Catani, J. P., Hannani, D., Duret, H., Steegh, K., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.03.003 · Cited by 699
Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells.
Roninson, I. B., Chin, J. E., Choi, K. G., Gros, P., Housman, D. E., Fojo, A., Shen, D. W., Gottesman, M. M., & Pastan, I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4538 · Cited by 686
Regulated cell death pathways in doxorubicin-induced cardiotoxicity
Christidi, E., & Brunham, L. R. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03614-x · Cited by 684
Li, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update
Mao, Q., & Unadkat, J. D. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9668-6 · Cited by 670
Kovalchuk, O., Filkowski, J., Meservy, J., Ilnytskyy, Y., Tryndyak, V. P., Chekhun, V. F., & Pogribny, I. P. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0021 · Cited by 635
Davies, K. J., & Doroshow, J. H. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35746-0 · Cited by 631
Adriamycin, 14‐hydroxydaimomycin, a new antitumor antibiotic from S. Peucetius var. caesius
Arcamone, F., Cassinelli, G., Fantini, G., Grein, A., Orezzi, P., Pol, C., & Spalla, C. (1969) · Biotechnology and Bioengineering · doi:10.1002/bit.260110607 · Cited by 622
Alkylating DNA damage stimulates a regulated form of necrotic cell death
Zong, W.-X., Ditsworth, D., Bauer, D. E., Wang, Z.-Q., & Thompson, C. B. (2004) · Genes & Development · doi:10.1101/gad.1199904 · Cited by 618
Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism
Hanada, K. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(03)00059-3 · Cited by 616
Doxorubicin Induces Apoptosis in Normal and Tumor Cells via Distinctly Different Mechanisms
Wang, S., Konorev, E. A., Kotamraju, S., Joseph, J., Kalivendi, S., & Kalyanaraman, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400944200 · Cited by 611
Polymeric nanoparticles: Promising platform for drug delivery
El-Say, K. M., & El-Sawy, H. S. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.06.052 · Cited by 608
CD13 is a therapeutic target in human liver cancer stem cells
Haraguchi, N., Ishii, H., Mimori, K., Tanaka, F., Ohkuma, M., Kim, H. M., Akita, H., Takiuchi, D., Hatano, H., Nagano, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42550 · Cited by 605
Human Multidrug-Resistant Cell Lines: Increased mdr 1 Expression Can Precede Gene Amplification
Shen, D.-W., Fojo, A., Chin, J. E., Roninson, I. B., Richert, N., Pastan, I., & Gottesman, M. M. (1986) · Science · doi:10.1126/science.3457471 · Cited by 603
Challis, G. L., & Hopwood, D. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934677100 · Cited by 597
Bernardi, P., Rasola, A., Forte, M., & Lippe, G. (2015) · Physiological Reviews · doi:10.1152/physrev.00001.2015 · Cited by 577
ABCB5-Mediated Doxorubicin Transport and Chemoresistance in Human Malignant Melanoma
Frank, N. Y., Margaryan, A., Huang, Y., Schatton, T., Waaga-Gasser, A. M., Gasser, M., Sayegh, M. H., Sadee, W., & Frank, M. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3327 · Cited by 574
Leith, C. P., Kopecky, K. J., Chen, I. M., Eijdems, L., Slovak, M. L., McConnell, T. S., Head, D. R., Weick, J. K., Grever, M. R., Appelbaum, F. R., et al. (1999) · PubMed · doi:10.1182/blood.v94.3.1086.415k32_1086_1099 · Cited by 573
MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression
Ivanovska, I., Ball, A. S., Diaz, R. L., Magnus, J. F., Kibukawa, M., Schelter, J. M., Kobayashi, S. V., Lim, L., Burchard, J., Jackson, A. L., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01977-07 · Cited by 561
Targeting the PI3K signaling pathway in cancer
Wong, K.-K., Engelman, J. A., & Cantley, L. C. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.11.002 · Cited by 543
Liang, M., Fan, K., Zhou, M., Duan, D., Zheng, J., Yang, D., Feng, J., & Yan, X. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407808111 · Cited by 507
Impact of Drug Transporter Studies on Drug Discovery and Development
Mizuno, N., Niwa, T., Yotsumoto, Y., & Sugiyama, Y. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.1 · Cited by 490
Bacterial solutions to multicellularity: a tale of biofilms, filaments and fruiting bodies
Claessen, D., Rozen, D. E., Kuipers, O. P., Søgaard-Andersen, L., & van Wezel, G. P. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3178 · Cited by 488
Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Palmeira, A., Sousa, E., H. Vasconcelos, M., & M. Pinto, M. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800167392 · Cited by 484
Zhou, H.-M., Zhang, J.-G., Zhang, X., & Li, Q. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00430-1 · Cited by 472
Structural insight into substrate and inhibitor discrimination by human P-glycoprotein
Alam, A., Kowal, J., Broude, E., Roninson, I., & Locher, K. P. (2019) · Science · doi:10.1126/science.aav7102 · Cited by 469
Shibata, T., Kokubu, A., Gotoh, M., Ojima, H., Ohta, T., Yamamoto, M., & Hirohashi, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.082 · Cited by 468
Doxorubicin Blocks Cardiomyocyte Autophagic Flux by Inhibiting Lysosome Acidification
Li, D. L., Wang, Z. V., Ding, G., Tan, W., Luo, X., Criollo, A., Xie, M., Jiang, N., May, H., Kyrychenko, V., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.017443 · Cited by 464
Zhu, H., Wu, H., Liu, X., Evans, B. R., Medina, D. J., Liu, C.-G., & Yang, J.-M. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.06.007 · Cited by 456
Tanaka, Y., Kamohara, H., Kinoshita, K., Kurashige, J., Ishimoto, T., Iwatsuki, M., Watanabe, M., & Baba, H. (2013) · Cancer · doi:10.1002/cncr.27895 · Cited by 446
MAPK/JNK signalling: a potential autophagy regulation pathway
Zhou, Y.-Y., Li, Y., Jiang, W.-Q., & Zhou, L.-F. (2015) · Bioscience Reports · doi:10.1042/bsr20140141 · Cited by 444
Early menopause in long-term survivors of cancer during adolescence
Byrne, J., Fears, T. R., Gail, M. H., Pee, D., Connelly, R. R., Austin, D. F., Holmes, G. F., Holmes, F. F., Latourette, H. B., Meigs, J. W., et al. (1992) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(92)91335-8 · Cited by 439
Trock, B. J., Leonessa, F., & Clarke, R. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.13.917 · Cited by 434
Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis
Pastushenko, I., Mauri, F., Song, Y., de Cock, F., Meeusen, B., Swedlund, B., Impens, F., Van Haver, D., Opitz, M., Thery, M., et al. (2021) · Nature · doi:10.1038/s41586-020-03046-1 · Cited by 429
23 Genetic instability induced by the tumor microenvironment
Glazer, P. M., Reynolds, T. Y., & Rockwell, S. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)80581-0 · Cited by 427
ABC transporters as mediators of drug resistance and contributors to cancer cell biology
Fletcher, J. I., Williams, R. T., Henderson, M. J., Norris, M. D., & Haber, M. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.03.001 · Cited by 423
Pang, B., Qiao, X., Janssen, L., Velds, A., Groothuis, T., Kerkhoven, R., Nieuwland, M., Ovaa, H., Rottenberg, S., van Tellingen, O., et al. (2013) · Nature Communications · doi:10.1038/ncomms2921 · Cited by 420
Chen, W.-X., Liu, X.-M., Lv, M.-M., Chen, L., Zhao, J.-H., Zhong, S.-L., Ji, M.-H., Hu, Q., Luo, Z., Wu, J.-Z., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095240 · Cited by 420
New insights into the activities and toxicities of the old anticancer drug doxorubicin
van der Zanden, S. Y., Qiao, X., & Neefjes, J. (2021) · The FEBS Journal · doi:10.1111/febs.15583 · Cited by 410
Wang, A. H. J., Ughetto, G., Quigley, G. J., & Rich, A. (1987) · Biochemistry · doi:10.1021/bi00378a025 · Cited by 405
Fornari, F., Gramantieri, L., Giovannini, C., Veronese, A., Ferracin, M., Sabbioni, S., Calin, G. A., Grazi, G. L., Croce, C. M., Tavolari, S., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4797 · Cited by 401
Fornari, F., Milazzo, M., Chieco, P., Negrini, M., Calin, G. A., Grazi, G. L., Pollutri, D., Croce, C. M., Bolondi, L., & Gramantieri, L. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0145 · Cited by 396
Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies
Liston, D. R., & Davis, M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3083 · Cited by 395
Ferritin Nanocarrier Traverses the Blood Brain Barrier and Kills Glioma
Fan, K., Jia, X., Zhou, M., Wang, K., Conde, J., He, J., Tian, J., & Yan, X. (2018) · ACS Nano · doi:10.1021/acsnano.7b06969 · Cited by 395
Chin, K. V., Tanaka, S., Darlington, G., Pastan, I., & Gottesman, M. M. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)40219-6 · Cited by 393
Transcriptional regulation of ABC drug transporters
Scotto, K. W. (2003) · Oncogene · doi:10.1038/sj.onc.1206950 · Cited by 392
Collateral Damage in Cancer Chemotherapy: Oxidative Stress in Nontargeted Tissues
Chen, Y., Jungsuwadee, P., Vore, M., Butterfield, D. A., & St. Clair, D. K. (2007) · Molecular Interventions · doi:10.1124/mi.7.3.6 · Cited by 387
Shedden, K., Xie, X. T., Chandaroy, P., Chang, Y., & Rosania, G. R. (2003) · PubMed · Cited by 385
Takahashi, K., Yan, I. K., Kogure, T., Haga, H., & Patel, T. (2014) · FEBS Open Bio · doi:10.1016/j.fob.2014.04.007 · Cited by 376
Green, D. M., Whitton, J. A., Stovall, M., Mertens, A. C., Donaldson, S. S., Ruymann, F. B., Pendergrass, T. W., & Robison, L. L. (2002) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2002.126643 · Cited by 372
Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity
Lotrionte, M., Biondi-Zoccai, G., Abbate, A., Lanzetta, G., D'Ascenzo, F., Malavasi, V., Peruzzi, M., Frati, G., & Palazzoni, G. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.08.026 · Cited by 371
Co-Delivery of siRNA and An Anticancer Drug for Treatment of Multidrug-Resistant Cancer
Saad, M., Garbuzenko, O. B., & Minko, T. (2008) · Nanomedicine · doi:10.2217/17435889.3.6.761 · Cited by 367
MicroRNAs modulate the chemosensitivity of tumor cells
Blower, P. E., Chung, J.-H., Verducci, J. S., Lin, S., Park, J.-K., Dai, Z., Liu, C.-G., Schmittgen, T. D., Reinhold, W. C., Croce, C. M., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0573 · Cited by 364
Challagundla, K. B., Wise, P. M., Neviani, P., Chava, H., Murtadha, M., Xu, T., Kennedy, R., Ivan, C., Zhang, X., Vannini, I., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv135 · Cited by 359
Eom, Y.-W., Kim, M. A., Park, S. S., Goo, M. J., Kwon, H. J., Sohn, S., Kim, W.-H., Yoon, G., & Choi, K. S. (2005) · Oncogene · doi:10.1038/sj.onc.1208627 · Cited by 351
Burger, H., Foekens, J. A., Look, M. P., Gelder, M. E. M., Klijn, J. G. M., Wiemer, E. A. C., Stoter, G., & Nooter, K. (2003) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 341
Kivisto, K., Kroemer, H., & Eichelbaum, M. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb05796.x · Cited by 340
Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy
Silva, R., Vilas-Boas, V., Carmo, H., Dinis-Oliveira, R. J., Carvalho, F., de Lourdes Bastos, M., & Remião, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.013 · Cited by 339
Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors
Mattarollo, S. R., Loi, S., Duret, H., Ma, Y., Zitvogel, L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0753 · Cited by 333
Liang, Z., Wu, H., Xia, J., Li, Y., Zhang, Y., Huang, K., Wagar, N., Yoon, Y., Cho, H. T., Scala, S., et al. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.10.017 · Cited by 330
Jackson, J. G., Pant, V., Li, Q., Chang, L. L., Quintás-Cardama, A., Garza, D., Tavana, O., Yang, P., Manshouri, T., Li, Y., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.027 · Cited by 329
Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells
Bebawy, M., Combes, V, Lee, E., Jaiswal, R., Gong, J., Bonhoure, A., & Grau, G. E. R. (2009) · Leukemia · doi:10.1038/leu.2009.76 · Cited by 322
Doxorubicin-DNA Adducts Induce a Non-Topoisomerase II–Mediated Form of Cell Death
Swift, L. P., Rephaeli, A., Nudelman, A., Phillips, D. R., & Cutts, S. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3410 · Cited by 314
HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma
Xiao, X., Wang, W., Li, Y., Yang, D., Li, X., Shen, C., Liu, Y., Ke, X., Guo, S., & Guo, Z. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0880-6 · Cited by 311
The combined status of ATM and p53 link tumor development with therapeutic response
Jiang, H., Reinhardt, H. C., Bartkova, J., Tommiska, J., Blomqvist, C., Nevanlinna, H., Bartek, J., Yaffe, M. B., & Hemann, M. T. (2009) · Genes & Development · doi:10.1101/gad.1815309 · Cited by 304
Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism
Meredith, A.-M., & Dass, C. R. (2016) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12539 · Cited by 303
Rafiyath, S. M., Rasul, M., Lee, B., Wei, G., Lamba, G., & Liu, D. (2012) · Experimental Hematology & Oncology · doi:10.1186/2162-3619-1-10 · Cited by 302
Topoisomerase levels determine chemotherapy response in vitro and in vivo
Burgess, D. J., Doles, J., Zender, L., Xue, W., Ma, B., McCombie, W. R., Hannon, G. J., Lowe, S. W., & Hemann, M. T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803513105 · Cited by 300
Kim, S.-Y., Kim, S.-J., Kim, B.-J., Rah, S.-Y., Chung, S. M., Im, M.-J., & Kim, U.-H. (2006) · Experimental & Molecular Medicine · doi:10.1038/emm.2006.63 · Cited by 297
Anderson, R. A., Mitchell, R. T., Kelsey, T. W., Spears, N., Telfer, E. E., & Wallace, W. H. B. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00039-x · Cited by 293
Amplification and Expression of Genes Associated with Multidrug Resistance in Mammalian Cells
Scotto, K. W., Biedler, J. L., & Melera, P. W. (1986) · Science · doi:10.1126/science.2421411 · Cited by 287
Xu, J., Liu, D., Niu, H., Zhu, G., Xu, Y., Ye, D., Li, J., & Zhang, Q. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0487-8 · Cited by 283
Exosomes Increase the Therapeutic Index of Doxorubicin in Breast and Ovarian Cancer Mouse Models
Hadla, M., Palazzolo, S., Corona, G., Caligiuri, I., Canzonieri, V., Toffoli, G., & Rizzolio, F. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0154 · Cited by 282
Van der Bliek, A. M., Baas, F., Ten Houte de Lange, T., Kooiman, P. M., Van der Velde-Koerts, T., & Borst, P. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02653.x · Cited by 281
Bao, L., Hazari, S., Mehra, S., Kaushal, D., Moroz, K., & Dash, S. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.02.024 · Cited by 275
Extracellular vesicles and anti-cancer drug resistance
Namee, N. M., & O'Driscoll, L. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.003 · Cited by 274
Ciavardelli, D., Rossi, C., Barcaroli, D., Volpe, S., Consalvo, A., Zucchelli, M., De Cola, A., Scavo, E., Carollo, R., D'Agostino, D., et al. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.285 · Cited by 269
Autophagy in cardiac myocyte homeostasis, aging, and pathology
TERMAN, A., & BRUNK, U. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.08.014 · Cited by 266
Classen, S., Olland, S., & Berger, J. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1832879100 · Cited by 263
Taylor, S., Spugnini, E. P., Assaraf, Y. G., Azzarito, T., Rauch, C., & Fais, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.08.004 · Cited by 259
Leonard, R. C. F., Williams, S., Tulpule, A., Levine, A. M., & Oliveros, S. (2009) · The Breast · doi:10.1016/j.breast.2009.05.004 · Cited by 257
Ward, A. B., Szewczyk, P., Grimard, V., Lee, C.-W., Martinez, L., Doshi, R., Caya, A., Villaluz, M., Pardon, E., Cregger, C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309275110 · Cited by 256
Classification Analysis of P-Glycoprotein Substrate Specificity
Didziapetris, R., Japertas, P., Avdeef, A., & Petrauskas, A. (2003) · Journal of Drug Targeting · doi:10.1080/10611860310001648248 · Cited by 253
Energy transduction and alternating access of the mammalian ABC transporter P-glycoprotein
Verhalen, B., Dastvan, R., Thangapandian, S., Peskova, Y., Koteiche, H. A., Nakamoto, R. K., Tajkhorshid, E., & Mchaourab, H. S. (2017) · Nature · doi:10.1038/nature21414 · Cited by 248
PARP-1 is involved in autophagy induced by DNA damage
Muñoz-Gámez, J. A., Rodríguez-Vargas, J. M., Quiles-Pérez, R., Aguilar-Quesada, R., Martín-Oliva, D., de Murcia, G., de Murcia, J. M., Almendros, A., de Almodóvar, M. R., & Oliver, F. J. (2009) · Autophagy · doi:10.4161/auto.5.1.7272 · Cited by 247
Nox2 NADPH Oxidase Promotes Pathologic Cardiac Remodeling Associated with Doxorubicin Chemotherapy
Zhao, Y., McLaughlin, D., Robinson, E., Harvey, A. P., Hookham, M. B., Shah, A. M., McDermott, B. J., & Grieve, D. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2664 · Cited by 244
Mamot, C., Ritschard, R., Wicki, A., Stehle, G., Dieterle, T., Bubendorf, L., Hilker, C., Deuster, S., Herrmann, R., & Rochlitz, C. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70476-x · Cited by 244
Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer
Cheung, E. C., DeNicola, G. M., Nixon, C., Blyth, K., Labuschagne, C. F., Tuveson, D. A., & Vousden, K. H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.012 · Cited by 243
Regulation of antibiotic production in Actinobacteria: new perspectives from the post-genomic era
van der Heul, H. U., Bilyk, B. L., McDowall, K. J., Seipke, R. F., & van Wezel, G. P. (2018) · Natural Product Reports · doi:10.1039/c8np00012c · Cited by 242
Wang, X. Q., Ongkeko, W. M., Chen, L., Yang, Z. F., Lu, P., Chen, K. K., Lopez, J. P., Poon, R. T. P., & Fan, S. T. (2010) · Hepatology · doi:10.1002/hep.23692 · Cited by 238
MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11
Bockhorn, J., Dalton, R., Nwachukwu, C., Huang, S., Prat, A., Yee, K., Chang, Y.-F., Huo, D., Wen, Y., Swanson, K. E., et al. (2013) · Nature Communications · doi:10.1038/ncomms2393 · Cited by 237
Agarwal, A., Mackey, M. A., El-Sayed, M. A., & Bellamkonda, R. V. (2011) · ACS Nano · doi:10.1021/nn201010q · Cited by 232
Abolhoda, A., Wilson, A. E., Ross, H., Danenberg, P. V., BURT, M. E., & Scotto, K. W. (1999) · PubMed · Cited by 231
Palazzolo, S., Bayda, S., Hadla, M., Caligiuri, I., Corona, G., Toffoli, G., & Rizzolio, F. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170830113755 · Cited by 225
Cao, Z., Ding, B.-S., Guo, P., Lee, S. B., Butler, J. M., Casey, S. C., Simons, M., Tam, W., Felsher, D. W., Shido, K., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.005 · Cited by 223
Chemotherapy medication errors
Weingart, S. N., Zhang, L., Sweeney, M., & Hassett, M. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30094-9 · Cited by 223
Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis
Wallace, K. B. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0008-2 · Cited by 221
Press, M. F., Sauter, G., Buyse, M., Bernstein, L., Guzman, R., Santiago, A., Villalobos, I. E., Eiermann, W., Pienkowski, T., Martin, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5644 · Cited by 219
Münster, P., Marchion, D., Bicaku, E., Schmitt, M., Lee, J. H., DeConti, R., Simon, G., Fishman, M., Minton, S., Garrett, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.6165 · Cited by 216
Rushworth, S. A., MacEwan, D. J., & O’Connell, M. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6730 · Cited by 215
Therapy-Related Acute Promyelocytic Leukemia
Beaumont, M., Sanz, M., Carli, P. M., Maloisel, F., Thomas, X., Detourmignies, L., Guerci, A., Gratecos, N., Rayon, C., San Miguel, J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.072 · Cited by 215
PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches
Ligresti, G., Militello, L., Steelman, L. S., Cavallaro, A., Basile, F., Nicoletti, F., Stivala, F., McCubrey, J. A., & Libra, M. (2009) · Cell Cycle · doi:10.4161/cc.8.9.8255 · Cited by 214
Chaires, J. B., Herrera, J. E., & Waring, M. J. (1990) · Biochemistry · doi:10.1021/bi00478a006 · Cited by 214
Valproic Acid Alters Chromatin Structure by Regulation of Chromatin Modulation Proteins
Marchion, D. C., Bicaku, E., Daud, A. I., Sullivan, D. M., & Munster, P. N. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2478 · Cited by 212
Xu, Y., Xia, F., Ma, L., Shan, J., Shen, J., Yang, Z., Liu, J., Cui, Y., Bian, X., Bie, P., et al. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.06.027 · Cited by 210
Molecular Pharmacology of ABCG2 and Its Role in Chemoresistance
Stacy, A. E., Jansson, P. J., & Richardson, D. R. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.088609 · Cited by 210
Li, L., ten Hagen, T. L. M., Hossann, M., Süss, R., van Rhoon, G. C., Eggermont, A. M. M., Haemmerich, D., & Koning, G. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.03.011 · Cited by 208
Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy in Breast Cancer
Varghese, E., Samuel, S. M., Líšková, A., Samec, M., Kubatka, P., & Büsselberg, D. (2020) · Cancers · doi:10.3390/cancers12082252 · Cited by 208
Osborn, M. T., & Chambers, T. C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.48.30950 · Cited by 207
P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy
Grogan, T., Spier, C., Salmon, S., Matzner, M., Rybski, J., Weinstein, R., Scheper, R., & Dalton, W. (1993) · Blood · doi:10.1182/blood.v81.2.490.490 · Cited by 207
Jin, F., Wang, Y., Li, M., Zhu, Y., Liang, H., Wang, C., Wang, F., Zhang, C.-Y., Zen, K., & Li, L. (2017) · Cell Death & Disease · doi:10.1038/cddis.2016.461 · Cited by 206
SERPINH1 regulates EMT and gastric cancer metastasis via the Wnt/β-catenin signaling pathway
Tian, S., Peng, P., Li, J., Deng, H., Zhan, N., Zeng, Z., & Dong, W. (2020) · Aging · doi:10.18632/aging.102831 · Cited by 205
Dhakshinamoorthy, S., & Jaiswal, A. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003531200 · Cited by 203
Marty, M., Espié, M., Llombart, A., Monnier, A., Rapoport, B. L., & Stahalova, V. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj134 · Cited by 202
Autophagy and doxorubicin resistance in cancer
Chen, C., Lu, L., Yan, S., Yi, H., Yao, H., Wu, D., He, G., Tao, X., & Deng, X. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000572 · Cited by 202
Caspase inhibition switches doxorubicin-induced apoptosis to senescence
Rebbaa, A., Zheng, X., Chou, P. M., & Mirkin, B. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206366 · Cited by 201
Structure of the adriamycin-cardiolipin complex
Goormaghtigh, E., Huart, P., Praet, M., Brasseur, R., & Ruysschaert, J.-M. (1990) · Biophysical Chemistry · doi:10.1016/0301-4622(90)80012-v · Cited by 200
ABCG2 transports anticancer drugs via a closed-to-open switch
Orlando, B. J., & Liao, M. (2020) · Nature Communications · doi:10.1038/s41467-020-16155-2 · Cited by 198
A chemical defence against phage infection
Kronheim, S., Daniel-Ivad, M., Duan, Z., Hwang, S., Wong, A. I., Mantel, I., Nodwell, J. R., & Maxwell, K. L. (2018) · Nature · doi:10.1038/s41586-018-0767-x · Cited by 197
Multidrug Resistance Proteins (MRPs) and Cancer Therapy
Zhang, Y.-K., Wang, Y.-J., Gupta, P., & Chen, Z.-S. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9757-1 · Cited by 196
Genes amplified and overexpressed in human multidrug-resistant cell lines.
van der Bliek, A. M., Baas, F., der Velde-Koerts, T. V., Biedler, J. L., Meyers, M. B., Ozols, R. F., Hamilton, T. C., Joenje, H., & Borst, P. (1988) · PubMed · Cited by 195
New signal transduction paradigms in anthracycline-induced cardiotoxicity
Ghigo, A., Li, M., & Hirsch, E. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.01.021 · Cited by 194
NF-κB-mediated Induction of mdr1b Expression by Insulin in Rat Hepatoma Cells
Zhou, G., & Kuo, M. T. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.24.15174 · Cited by 193
Long non-coding RNAs in the doxorubicin resistance of cancer cells
Ashrafizaveh, S., Ashrafizadeh, M., Zarrabi, A., Husmandi, K., Zabolian, A., Shahinozzaman, M., Aref, A. R., Hamblin, M. R., Nabavi, N., Crea, F., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.018 · Cited by 192
Cai, Q., Wang, S., Jin, L., Weng, M., Zhou, D., Wang, J., Tang, Z., & Quan, Z. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1016-0 · Cited by 190
Fornari, F., Milazzo, M., Chieco, P., Negrini, M., Marasco, E., Capranico, G., Mantovani, V., Marinello, J., Sabbioni, S., Callegari, E., et al. (2012) · The Journal of Pathology · doi:10.1002/path.3995 · Cited by 189
Redox active calcium ion channels and cell death
Waring, P. (2005) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2004.08.001 · Cited by 189
Targeting of miR34a–NOTCH1 Axis Reduced Breast Cancer Stemness and Chemoresistance
Park, E. Y., Chang, E., Lee, E. J., Lee, H.-W., Kang, H.-G., Chun, K.-H., Woo, Y. M., Kong, H. K., Ko, J. Y., Suzuki, H., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1140 · Cited by 188
Chen, J., Zhang, B., Wong, N., Lo, A. W. I., To, K.-F., Chan, A. W. H., Ng, M. H. L., Ho, C. Y. S., Cheng, S.-H., Lai, P. B. S., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4274 · Cited by 188
FOXO3-induced reactive oxygen species are regulated by BCL2L11 (Bim) and SESN3
Hagenbuchner, J., Kuznetsov, A., Hermann, M., Hausott, B., Obexer, P., & Ausserlechner, M. J. (2012) · Journal of Cell Science · doi:10.1242/jcs.092098 · Cited by 187
Mechanisms of doxorubicin resistance in hepatocellular carcinoma
Cox, J., & Weinman, S. (2016) · Hepatic Oncology · doi:10.2217/hep.15.41 · Cited by 187
Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1
Alam, A., Küng, R., Kowal, J., McLeod, R. A., Tremp, N., Broude, E. V., Roninson, I. B., Stahlberg, H., & Locher, K. P. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717044115 · Cited by 187
Mirzaei, S., Gholami, M. H., Hashemi, F., Zabolian, A., Farahani, M. V., Hushmandi, K., Zarrabi, A., Goldman, A., Ashrafizadeh, M., & Orive, G. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2021.09.020 · Cited by 186
van der Zee, A. G., Hollema, H., Suurmeijer, A. J., Krans, M., Sluiter, W. J., Willemse, P. H., Aalders, J. G., & de Vries, E. G. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.70 · Cited by 184
Hui, R. C.-Y., Francis, R. E., Guest, S. K., Costa, J. R., Gomes, A. R., Myatt, S. S., Brosens, J. J., & Lam, E. W.-F. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0397 · Cited by 184
Metadata
- Authors
- Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G.
- Venue
- Molecular Aspects of Medicine
- Publisher
- Elsevier BV
- Published
- 2023-10
- Volume
- 93
- Pages
- 101205
- ISSN
- 0098-2997 (ISSN-L)
- OpenAlex
- W4385325206
- Cited by
- 294
- References
- 587
- FWCI
- 21.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.